I am an Associate Professor of Epidemiology at the University of Pittsburgh. I am also Associate Professor at the International Health at Johns Hopkins Bloomberg School of Public Health; and Professor Extraordinary of Medicine at Stellenbosch University, Cape Town, South Africa. I received my training in Belgium (University of Louvain), UK (London School of Hygiene & Tropical Medicine), USA (Johns Hopkins University & Harvard University). I have over 25 year-experience in patient care, teaching, designing and implementing HIV/AIDS and Tuberculosis studies or programs funded by NIH/NIAID, PEPFAR, EDCTP, and Wellcome Trust. I’ve authored more than 200 peer-reviewed publications including in top-tier journals such as The Lancet, The New England Journal of Medicine, JAMA, Clinical Infectious Diseases and Annals of Internal Medicine. I am an ad hoc consultant at WHO, CDC, Bill and Melinda Gates Foundation, as well as a member of Academy of Sciences of South Africa (ASSAf) and African Academy of Sciences (AAS)
1985 \ Facultes Universitaires Notre Dame de la Paix, Namur, Belgium\ BS (Cum Laude)
1989 \ University Catholic of Louvain, Brussels, Belgium \ MD (Cum Laude)
1999 \ Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA \ MPH
2000 \ London School of Hygiene & Tropical Medicine, London, UK \ DTM&H
2008 \ University of Cape Town, South Africa \ PhD
2010 \ Harvard School of Public Health, Boston, MA, USA \ John McGoldrick Fellow in Biostat in AIDS Research, Decision Analysis and Health Economics
• Primary Instructor: A) EPIDEM2160, Infectious Diseases Epidemiology (Two Credits); B) EPIDEM2166, Global Control of Tuberculosis & HIV, SPRING Term (One Credit); C) EPIDEM2162, Infectious Diseases & Global Health, FALL Term (Two Credits).
Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, Nachman S, Decloedt E, Geng EH, Wilson L, Rawat A, Mellors JW.
Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023 May;10(5):e332-e342. doi: 10.1016/S2352-3018(23)00051-6. Epub 2023 Apr 14. PMID: 37062293; PMCID: PMC10734401.
Bidashimwa D, Ditekemena JD, Sigwadhi LN, Nkuta LM, Engetele E, Kilundu A, Chabikuli ON, Nachega JB.
Completion of isoniazid preventive therapy for latent tuberculosis infection among children and adolescents compared to adults living with HIV in Kinshasa, Democratic Republic of the Congo. Trop Med Int Health. 2024 Feb;29(2):88-95. doi: 10.1111/tmi.13952. Epub 2023 Dec 20. PMID: 38123460.
GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8. Erratum in: Lancet. 2017 Jan 7;389(10064):e1. doi: 10.1016/S0140-6736(16)32632-0. PMID: 27733284; PMCID: PMC5388856.
Uthman OA, Nachega JB, Anderson J, Kanters S, Mills EJ, Renaud F, Essajee S, Doherty MC, Mofenson LM. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV. 2017 Jan;4(1):e21-e30. doi: 10.1016/S2352-3018(16)30195-3. Epub 2016 Nov 16. PMID: 27864000.
Nachega JB, Uthman OA, Peltzer K, Richardson LA, Mills EJ, Amekudzi K, Ouédraogo A. Association between antiretroviral therapy adherence and employment status: systematic review and meta-analysis. Bull World Health Organ. 2015 Jan 1;93(1):29-41. doi: 10.2471/BLT.14.138149. Epub 2014 Oct 30. PMID: 25558105; PMCID: PMC4271680.
Zeier MD, Nachega JB. Targeting HIV: past, present and future. Infect Disord Drug Targets. 2011 Apr;11(2):98-114. doi: 10.2174/187152611795589690. PMID: 21406054.
